

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

17414  
100303  
S.P.T.O.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonapplications under 37C.F.R. §1.53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

Attorney Docket No.	PC10925B
First Inventor	MANOUSSOS PERROS
Title	TROPANE DERIVATIVES USEFUL IN THERAPY
Express Mail Label No.	EL 969716642 US

22389 U.S. PTO  
10/678836  
100303

1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i>	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)	
2. <input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27	8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>	
3. <input checked="" type="checkbox"/> Specification [Total Pages 79] <i>(preferred arrangement set forth below)</i> <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R&amp;D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (<i>if filed</i>)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul>	a. <input type="checkbox"/> Computer Readable Copy (CRF)	
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total sheets 0]	b. Specification Sequence Listing on: <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies)</li> <li>ii. <input type="checkbox"/> Paper</li> </ul>	
5. <input checked="" type="checkbox"/> Oath or Declaration [Total pages 3] <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Newly executed (original or copy)</li> <li>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li> </ul> </li> </ul>	c. <input type="checkbox"/> Statement verifying identity of above copies	
6.. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	<b>ACCOMPANYING APPLICATION PARTS</b>	
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.	<input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s)) <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input checked="" type="checkbox"/> Power of Attorney <input type="checkbox"/> English Translation Document ( <i>if applicable</i> ) <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations <input checked="" type="checkbox"/> Preliminary Amendment <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. <input checked="" type="checkbox"/> Other: Copy of Priority Assignment papers	

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.

Continuation     Divisional     Continuation-in-part (CIP)    of prior application No: 09/865,950

Prior application information: Examiner Evelyn Huang Group/Art Unit: 1614

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

**19. CORRESPONDENCE ADDRESS**

<input checked="" type="checkbox"/> Customer Number	28940		or <input type="checkbox"/> Correspondence address below		
Name	Pfizer Inc.				
Address	10777 Science Center Drive				
City	San Diego	State	CA	Zip Code	92121
Country	USA	Telephone	858-526-4608	Fax	858-678-8233
NAME (Print/type)	Keith D. Hutchinson		Registration No. (Attorney/Agent)	43,687	
Signature			Date	October 3, 2003	

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL  
for FY 2003**

Effective 01/01/2003. Patent fees are subject to annual revision.

 Applicant claims small status. See 37 CFR 1.27**Total Amount of Payment** (\$770)**METHOD OF PAYMENT** (check all that apply)
 Check  Credit Card  Money  Other  None  
Order
 Deposit Account:

Deposit Account Number	500329
Deposit Account Name	Agouron Pharmaceuticals, Inc.

**The Director is authorized to:** (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) during the pendency of this application  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

**FEE CALCULATION****1. BASIC FILING FEE****Large Entity** **Small Entity**

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	770
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	filing fee	

Subtotal (1) \$ 770

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims	7	- 20 =	0	x	0	=	0	Fee from below	Fee Paid
Independent Claims	2	- 3 =	0	x	0	=	0		
Multiple Dependent									

Large Entity	Small Entity	Fee Description
Fee Code	Fee Code	
1202	18	2202 9 Claims in excess of 20
1201	84	2201 42 Independent claims in excess of 3
1203	280	2203 140 Multiple dependent claim, if not paid
1204	84	2204 42 **Reissue independent claims over original patent
1205	18	2205 9 **Reissue independent claims over original patent

SUBTOTAL (2) (\$ 0)

\*Reduced by Basic Filing Fee Paid

Subtotal (3) (\$ 0)

(Complete if applicable)

Name (Printed/Type)	Keith D. Hutchinson	Registration No.	43,687	Telephone	858-526-4608
Signature	Keith D. Hutchinson	Date	October 3, 2002		

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 137 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.



PC10925B

1741 U.S. PTO  
100303

**Certificate of Mailing (37 C.F.R. §1.10):**  
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (#EL969716642US) in an envelope addressed to: Mail Stop: Patent Application, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 3rd day of October 2003.

s/   
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re the Application of:**  
**M. Perros et al.****Group Art Unit: Not Yet Assigned****Serial No.: Not Yet Assigned****Examiner: Not Yet Assigned****Filed: Herewith****For: Tropane Derivatives Useful in Therapy****CONTINUATION APPLICATION UNDER 37 CFR 1.53(b)**

Mail Stop: Patent Applications  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Sir:**

This application is a continuation of recently allowed U.S. Serial No. 09/865,950, filed May 25, 2001. A copy of the specification, including a description and at least one claim, from U.S. Serial No. 09/865,950 is included herein.

A copy of the Oath/Declaration from the parent case (U.S. Serial No. 09/865,950) is included herein. A label clearly designating that the Oath/Declaration is a copy from the parent case is affixed to the front page of the Oath/Declaration.

Applicants also enclose herewith a Preliminary Amendment.

**Enclosures:**

1. Preliminary Amendment	4 pages;
2. Copy of Priority Assignment Papers	3 pages;
3. Declaration and Power of Attorney	3 pages;
4. Application Data Sheet	2 pages;
5. Utility Patent Application Transmittal	1 page;
6. Fee Transmittal	1 page + Duplicate;

7. Specification of 09/865,950
8. Basic Filing Fee \$770
9. Return Postcard

79 Total Pages.  
Deposit Account; and  
1 postcard.

Respectfully submitted,

Date: Oct. 03, 2003

Keith D. Hutchinson

Keith D. Hutchinson  
Attorney For Applicants  
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233